What is Erste Group Bank’s Estimate for LLY FY2027 Earnings?

Eli Lilly and Company (NYSE:LLY) – Equities researchers at Erste Group Bank lowered their FY2027 earnings estimates for shares of Eli Lilly and Company in a report issued on Thursday, June 25th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $44.66 for the year, down from their previous estimate of $44.74. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $35.74 per share.

A number of other equities research analysts have also weighed in on the stock. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Royal Bank Of Canada reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Weiss Ratings downgraded Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, May 19th. HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their target price for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Finally, Rothschild & Co Redburn lifted their target price on Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,235.07.

Eli Lilly and Company Stock Down 2.5%

Shares of NYSE LLY opened at $1,199.30 on Wednesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company has a 50-day moving average price of $1,048.18 and a 200-day moving average price of $1,024.30. The stock has a market capitalization of $1.13 trillion, a P/E ratio of 42.60, a P/E/G ratio of 1.35 and a beta of 0.53. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,238.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the company posted $3.34 earnings per share. The business’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS.

Institutional Trading of Eli Lilly and Company

A number of hedge funds have recently bought and sold shares of the business. Spire Wealth Management increased its position in shares of Eli Lilly and Company by 2.2% in the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after purchasing an additional 592 shares during the last quarter. Coldstream Capital Management Inc. lifted its position in Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after purchasing an additional 8,659 shares during the last quarter. Farther Finance Advisors LLC lifted its position in Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after purchasing an additional 7,338 shares during the last quarter. Teachers Retirement System of The State of Kentucky grew its stake in Eli Lilly and Company by 3.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock worth $126,022,000 after buying an additional 5,595 shares in the last quarter. Finally, Stonebridge Capital Advisors LLC grew its stake in Eli Lilly and Company by 318.1% in the 3rd quarter. Stonebridge Capital Advisors LLC now owns 10,519 shares of the company’s stock worth $8,026,000 after buying an additional 8,003 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly continues to benefit from enthusiasm around its weight-loss and diabetes franchise, with articles highlighting its dominance in the GLP-1 market and expectations for further long-term growth. Article Title
• Positive Sentiment: The FDA selected Eli Lilly for its PreCheck pilot program, which could speed reviews of new U.S. manufacturing facilities and support Lilly’s multi-billion-dollar capacity expansion. Article Title
• Positive Sentiment: Investors also reacted to Lilly’s expanding oncology reach in China and the commercialization agreement for Verzenios, which keeps Lilly involved in supply and development while adding local distribution support. Article Title
• Positive Sentiment: Separately, Lilly was highlighted in several bullish commentary pieces after hitting record highs and new 52-week highs, reinforcing momentum in the shares. Article Title
• Neutral Sentiment: Cliff Asness’ AQR Capital Management listed Lilly among its top healthcare holdings, which may support investor confidence but is not a direct operational catalyst. Article Title
• Negative Sentiment: The main pressure point is the handoff of mainland China commercialization rights for Verzenios to Innovent Biologics, which investors may view as a reduction in direct control over part of Lilly’s China business and a reason for some near-term selling. Article Title

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.